Non-α-biased IL-2 enhances both intratumoral and subcutaneous CpG/α-OX40 therapy, unleashing systemic antitumor immunity in mice
These findings demonstrate that non-α-biased IL-2 synergizes with CpG/α-OX40 to overcome microenvironmental immunosuppression and achieve systemic antitumor immunity via a subcutaneous route, offering a translatable combinatorial strategy for immune-cold tumors.
Authors
- Leying Zhou
- wenfeng li
- Ying He (ORCID: https://orcid.org/0000-0002-0072-8566)
- C. Chen
- Jianmin Li (ORCID: https://orcid.org/0000-0003-3315-6813)
- Xiaobo Ding
- Zhenghua Fei (ORCID: https://orcid.org/0000-0003-4021-3687)
- Kejie Huang
- Chunhong Zhang
- Chaoming Huang
- Yan Chen
- Zhixiang Bai
- Xujie Zhou
- Yi Jin
- Xuehuan Wen
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Sir Run Run Shaw Hospital (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/jitc-2025-012336
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bethune Charitable Foundation
- National Natural Science Foundation of China
- Wu Jieping Medical Foundation